Multiple sclerosis therapeutics

by Cohen, Jeffrey A., (Jeffrey Alan) Rudick, Richard A.

Type Book

Rate 0.0 /5

Details

Files

Reviews

Download

Title Statements

Full title :Multiple sclerosis therapeutics / edited by Jeffrey A. Cohen, Richard A. Rudick.

Summary

"This book comprehensively reviews the current state of clinical trial methods in multiple sclerosis treatment, providing investigators, sponsors and specialists with current knowledge of outcome measures and study designs for disease and symptom management. The status of the rapidly evolving field of disease-modifying drugs is presented, with emphasis on the most promising therapies currently being tested. Experts discuss disease and symptom management for MS subtypes, including neuromyelitis optica and pediatric MS. In addition, key scientific advances in MS pathology, genetics, immunology and epidemiology are presented. The fourth edition has been extensively revised, featuring more than 50% new material. All chapters have been substantially updated to provide current information on rapidly evolving topics and this volume contains 15 new chapters, reflecting the growth of the field in recent years. This book is an essential reference for practitioners caring for MS patients, investigators planning or conducting clinical trials, and clinical trial sponsors"--Provided by publisher

Edition Statements

Publication Date:2011.
Edition:4th ed

Publication Statements

Publisher(s):Cambridge University Press
Place of Publication:Cambridge, UK
Language:eng
Publication Date:2011.

The Physical Object

Description:1 online resource (xvii, 752 pages, [8] pages of color plates) : : illustrations (some color)

Edition Identifiers

ISBN:9781139161121, 1139161121, 1139157310, 9781139157315, 9781139159074, 1283342278, 9781283342278, 1139159070, 9781139023986, 1139023985, 9781107225008, 1107225000, 9781139155564, 1139155563
oclc:ocn773039601
LC Classification:RC377
Dewey Decimal:616.8/34

Cover; Multiple Sclerosis Therapeutics; Title; Copyright; Contents; Contributors; Abbreviations list; Foreword; Preface; 1 Aspects of multiple sclerosis that relate to experimental therapeutics; Disease features relevant to clinical trials; MS pathology is largely subclinical in early MS; Progressive destructive pathology starts early in the disease; Disease manifestations are heterogeneous; Evolution of the MS disease process- the "MS categories"; Disease severity can not be accurately predicted in individuals or groups; Heterogeneity in pathological mechanisms.

Complexities related to measurement tools that impact clinical trialsClinical measures: relapses, physical function, neuropsychological performance (Chapters 6-8); Patient-reported quality of life measures (Chapter8)56; Conventional MRI measures (Chapters 9,11); Current controversies in MS trials; Relapse rate; EDSS; Relevance of MRI lesions; The role of brain atrophy measures in MS trials; Gray matter pathology; Contemporary issues in MS trials; Optimal study designs for primary neuroprotection; Declining disease severity in contemporary MS trials.

Personalized medicine- from trials to patient careObservational and fol…

Subjects

Clinical Trials as Topic -- methods Évaluation des résultats (Soins médicau… HEALTH & FITNESS -- Diseases Imagerie par résonance magnétique Magnetic Resonance Imaging MEDICAL -- Neurology Multiple Sclerosis Multiple Sclerosis -- pathology Multiple Sclerosis -- therapy Outcome assessment (Medical care) Outcome Assessment, Health Care Sclérose en plaques